[1]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407-封3.
点击复制

SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年3期
页码:
407-封3
栏目:
综述
出版日期:
2019-03-05

文章信息/Info

文章编号:
DOI:10.3969/j.issn.10007377.2019.03.034
作者:
刘毅龙1; 陈鹏宇1; 雷 江1; 张 甜2; 杨 征3; 寿锡凌
1.西安医学院（西安 710021）；2.西安急救中心（西安 710018）；3.陕西省人民医院心血管内二科（西安 710068）
关键词:
2型糖尿病; 心血管疾病; SGLT2抑制剂; 恩格列净; 综述
分类号:
R587.1
文献标志码:
A
摘要:
摘 要 〖JP2〗2型糖尿病是心血管疾病常见危险因素及合并症，在两者合并的患者中如何进行安全有效的降糖治疗，SGLT2抑制剂在相关临床研究中表现出了明确心血管获益，成为治疗此类患者时的重要选择。本文拟针对SGLT2抑制剂相关研究的结果及其心血管获益可能的机制予以综述。

参考文献/References:

[1] 陈伟伟，高润霖，刘力生,等. 中国心血管病报告2017 [J].中国循环杂志，2018，33：18.
[2] 中华人民共和国国家卫生和计划生育委员会. 中国居民营养与慢性病状况报告(2015)\[R\].北京，2015. \[3\] 洪天配, 母义明, 纪立农,等. 2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识 [J].中国糖尿病杂志，2017，6：481492. 〖FL)〗 〖FL(K2〗〖HT5”SS〗\[4\] Singh S, Loke YK, Furberg CD. Longterm risk of cardiovascular events with rosiglitazone: a metaanalysis. [J].JAMA,2007，298:11891195. \[5\] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [J]. N Engl J Med, 2007，356(24):24572471.
[6] 〖JP4〗FDA. Guidance for industry diabetes mellitusevaluating cardiovascular risk in New Antidiabetic therapies to treat type 2 diabetes[J].Contains Nonbinding Recommendations,2008:118.〖JP〗
[7] Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus[J]. Annu Rev Med, 2015,66:255270.
[8] Zinman B, Wanner C, Lachin JM, et al. EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. [J].N Engl J Med, 2015,373(22):21172128.
[9] Raz I, Cahn A. Heart failure: SGLT2 inhibitors and heart failure – clinical implications. [J].Nat Rev Cardiol, 2016, 13(4) :185186. 
[10] Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017，377(7):644657.
[11] 〖JP3〗Kosiborod M, Cavender MA, Fu AZ, et al. CVDREAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodiumglucose cotransporter2 inhibitors versus other glucoselowering drugs: the CVDREAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodiumglucose cotransporter2 inhibitors)[J]. Circulation, 2017，136(3):249259.〖JP〗
[12] 〖JP3〗Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodiumglucose cotransporter2 inhibitors versus other glucoselowering drugs (CVDREAL Nordic): a multinational observational analysis [J]. Lancet Diabetes Endocrinol, 2017, 5(9):709717.〖JP〗
[13] Heise T, SeewaldtBecker E, Macha S, et al. Safety, tolerability, phar macokinetics and pharmacodynamics following 4 weeks’treatment with empagliflozin once daily in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2013, 15(7):613621.
[14] Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised, doubleblind, phase 3 noninferiority trial [J]. Lancet, 2013,382(9896):941950.
[15] Daniele G, Xiong J, SolisHerrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes [J]. Diabetes Care, 2016, 39(11):20362041.
[16] 〖JP3〗Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodiumglucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes [J].Diabetes, 2016, 65(5):11901195.〖JP〗
[17] Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction [J].FASEB J, 1995，9(8):651658.
[18] 〖JP2〗Tahara A, Kurosaki E, Yokono M, et al. Effects of sodiumglucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocininduced type 1 diabetic rats [J]. Pharm Pharmacol, 2014，66(7):975987.〖JP〗
[19] Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPAREG outcome study? A unifying hypothesis [J].Diabetes Care, 2016，39(7):11151122.
[20] 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识 [J]. 中华内科学杂志, 2017,56(3) : 235248.
[21] Tikkanen I, Chilton R, Johansen OE. Potential role of sodiumglucose cotransporter 2 inhibitors in the treatment of hypertension [J]. Curr Opin Nephrol Hypertens, 2016,25(2):8186.
[22] Tikkanen I, Narko K, Zeller C, et al. EMPAREG BP Investigators. Empagliflozin reduces bloodpressure in patients with type 2 diabetes and hypertension [J].Diabetes Care, 2015，38(3):420428.
[23] Townsend RR, Machin I, Ren J, et al. Reductions in mean 24hour ambulatory blood pressure after 6week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension [J]. Clin Hypertens (Greenwich), 2016，18(1):4352.
[24] Wanner C, Inzucchi SE, Lachin JM, et al. EMPAREG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016，375(4):323334.
[25] Jones BJ, Tan T, Bloom SR. Minireview: glucagon in stress and energy homeostasis[J].Endocrinology,2012，153(3):10491054.
[26] 〖JP3〗Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients [J]. Clin Invest, 2014，124(2):499508.〖JP〗
[27] Bonner C, KerrConte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion [J]. Nat Med, 2015，21(5):512517.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(3):77.
[3]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(3):518.
[4]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[5]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[6]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(3):1032.
[7]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(3):1163.
[8]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[9]郭建强,赵俊宏,张分队,等.2型糖尿病视网膜病变患者血清HbA1c、CysC检测及临床意义*[J].陕西医学杂志,2020,49(5):619.
　GUO Jianqiang,ZHAO Junhong,ZHANG Fendui,et al.Changes of serum HbA1c and CysC in patients with type 2 diabetic retinopathy and their clinical significance[J].,2020,49(3):619.
[10]陈伟国,朱萧玲,常 盼,等.2型糖尿病患者冠状动脉狭窄程度危险因素分析*[J].陕西医学杂志,2020,49(6):672.[doi:DOI:10.3969/j.issn.10007377.2020.06.008]
　CHEN Weiguo,ZHU Xiaoling,CHANG Pan,et al.Risk factors of coronary stenosis in patients with type 2 diabetes mellitus[J].,2020,49(3):672.[doi:DOI:10.3969/j.issn.10007377.2020.06.008]

更新日期/Last Update: 2019-03-15